Key Takeaways
- • California dominates U.S. life sciences venture capital allocation, with three of the top 10 regional clusters (San Francisco Bay at No. 2, San Diego at No. 3, and Los Angeles at No. 9) and 311,000+ employees across 3,400 life sciences organizations, according to CBRE's 2019 report.
- • Venture capital funding to the life sciences sector has reached "staggering" levels, with Massachusetts and California capturing 74% of new funding—though this concentration has declined as investors increasingly target emerging markets.
- • Washington, D.C.-Baltimore has emerged as the fastest-growing alternative hub, experiencing a nearly ninefold jump in venture capital funding within an 18-month period, signaling capital diversification beyond traditional coastal clusters.
- • Philadelphia, Chicago, Raleigh-Durham, and San Diego also recorded impressive gains in venture capital attraction over the 18 months covered by the analysis, indicating broader geographic dispersion of life sciences investment.
- • Strong industry organizations such as the California Life Sciences Association and MassBio play a critical role in ecosystem retention and growth, complementing venture capital availability to sustain competitive advantage in regional clusters.
Summary
Venture capital concentration in U.S. life sciences remains heavily weighted toward traditional innovation hubs, though emerging regions are beginning to capture meaningful investment flows. According to CBRE's 2019 U.S. Life Sciences Clusters report, California commands three positions in the top 10 regional rankings, with the San Francisco Bay Area at No. 2, San Diego at No. 3, and Los Angeles at No. 9. The state's dominance reflects both the scale of its life sciences workforce—exceeding 311,000 employees across 3,400 organizations—and the sustained concentration of venture capital infrastructure in the region.
The report characterizes the volume of new venture capital flowing into the life sciences sector as "staggering," with the vast majority directed toward biotech companies. Massachusetts and California combined account for 74% of this funding allocation, underscoring the persistence of coastal cluster dynamics. However, this geographic concentration has moderated over the preceding two years as institutional investors increasingly deploy capital into underserved markets, seeking higher-growth opportunities outside saturated traditional hubs.
The most dramatic shift appears in secondary markets. The Washington, D.C.-Baltimore region experienced venture capital funding growth of nearly ninefold within an 18-month window, establishing it as the leading emerging hub for life sciences investment. Philadelphia, Chicago, Raleigh-Durham, and San Diego similarly recorded substantial gains during the same period, indicating a deliberate reallocation toward markets with lower valuations and less mature competition.
Beyond capital availability, the durability of leading clusters correlates with institutional support structures. Industry organizations such as the California Life Sciences Association and MassBio (supporting Boston-Cambridge's No. 1 ranking) provide critical ecosystem functions—including policy advocacy, talent development, and deal-making infrastructure—that sustain competitive advantage and retain high-growth companies. Ian Anderson, director of research and analysis at CBRE, emphasizes that these organizational layers are "very important to keeping some of these companies, and keeping them flourishing and maintaining that economic base," suggesting that venture capital alone is insufficient to sustain long-term regional competitiveness without complementary institutional scaffolding.
The report characterizes the volume of new venture capital flowing into the life sciences sector as "staggering," with the vast majority directed toward biotech companies. Massachusetts and California combined account for 74% of this funding allocation, underscoring the persistence of coastal cluster dynamics. However, this geographic concentration has moderated over the preceding two years as institutional investors increasingly deploy capital into underserved markets, seeking higher-growth opportunities outside saturated traditional hubs.
The most dramatic shift appears in secondary markets. The Washington, D.C.-Baltimore region experienced venture capital funding growth of nearly ninefold within an 18-month window, establishing it as the leading emerging hub for life sciences investment. Philadelphia, Chicago, Raleigh-Durham, and San Diego similarly recorded substantial gains during the same period, indicating a deliberate reallocation toward markets with lower valuations and less mature competition.
Beyond capital availability, the durability of leading clusters correlates with institutional support structures. Industry organizations such as the California Life Sciences Association and MassBio (supporting Boston-Cambridge's No. 1 ranking) provide critical ecosystem functions—including policy advocacy, talent development, and deal-making infrastructure—that sustain competitive advantage and retain high-growth companies. Ian Anderson, director of research and analysis at CBRE, emphasizes that these organizational layers are "very important to keeping some of these companies, and keeping them flourishing and maintaining that economic base," suggesting that venture capital alone is insufficient to sustain long-term regional competitiveness without complementary institutional scaffolding.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.